Nearly five-million Americans are living with Alzheimer’s disease.
Drugs on the market can treat the symptoms, but none go after what causes it.
Now researchers are on the brink of a huge breakthrough with a drug that targets the cause and could stop the disease in its tracks.
Frances Goldstein has Alzheimer's disease.
He was diagnosed eight years ago at age 56.
Three years ago, she joined a study testing a drug that could change prognosis.
It is called Alzhemed it and attacks amyloid peptide, the molecule that causes Alzheimer’s in mice.
Dr. Paul Aisen of Georgetown University stated, "This drug is attacking the cause of Alzheimer’s disease. If it works, it will change the course of the disease and that will represent a real breakthrough."
An early study shows Alzhemed stabilized the disease in nearly half the patients.
Now more than 1,000 patients are being followed.
